Literature DB >> 19998512

Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.

Daniel Kaemmerer1, Vikas Prasad, Wolfgang Daffner, Dieter Hörsch, Günter Klöppel, Merten Hommann, Richard P Baum.   

Abstract

Pancreatic endocrine tumors are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis many of them are already advanced and difficult to treat. We report on an initially inoperable malignant pancreatic endocrine tumor in a 33-year-old woman, who received neoadjuvant peptide receptor radionuclide therapy (PRRT) as first-line treatment. This resulted in a significant downstaging of the tumor and allowed its subsequent complete surgical removal. Follow-up for eighteen months revealed a complete remission. This is the first report on neoadjuvant PRRT in a neuroendocrine neoplasm with subsequent successful complete resection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19998512      PMCID: PMC2791284          DOI: 10.3748/wjg.15.5867

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  [Tumors of the endocrine pancreas].

Authors:  M Anlauf; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

2.  Visualisation of a somatostatin receptor-expressing tumour with 67Ga-DOTATOC SPECT.

Authors:  K Zhernosekov; P Aschoff; D Filosofov; M Jahn; M Jennewein; H-J Adrian; H Bihl; F Rösch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09       Impact factor: 9.236

3.  Resection of pancreatic neuroendocrine tumors: results of 70 cases.

Authors:  Kevork K Kazanjian; Howard A Reber; Oscar J Hines
Journal:  Arch Surg       Date:  2006-08

4.  86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.

Authors:  François Jamar; Raffaella Barone; Isabelle Mathieu; Stéphan Walrand; Daniel Labar; Pascal Carlier; Joëlle de Camps; Horst Schran; TianLing Chen; M Charles Smith; Hakim Bouterfa; Roelf Valkema; Eric P Krenning; Larry K Kvols; Stanislas Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-12       Impact factor: 9.236

Review 5.  Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors.

Authors:  Henning Dralle; Sabine L Krohn; Wolfram Karges; Bernhard O Boehm; Michael Brauckhoff; Oliver Gimm
Journal:  World J Surg       Date:  2004-11-11       Impact factor: 3.352

6.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Authors:  Damian Wild; Jörg S Schmitt; Mihaela Ginj; Helmut R Mäcke; Bert F Bernard; Eric Krenning; Marion De Jong; Sandra Wenger; Jean-Claude Reubi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

7.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

8.  Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.

Authors:  Christiane Wehrmann; Stefan Senftleben; Carolin Zachert; Dirk Müller; Richard P Baum
Journal:  Cancer Biother Radiopharm       Date:  2007-06       Impact factor: 3.099

9.  Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.

Authors:  Naohiro Nomura; Tsutomu Fujii; Naohito Kanazumi; Shin Takeda; Shuji Nomoto; Hideki Kasuya; Hiroyuki Sugimoto; Suguru Yamada; Akimasa Nakao
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-04-14

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  19 in total

Review 1.  Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

Authors:  Sander M Bison; Mark W Konijnenberg; Marleen Melis; Stefan E Pool; Monique R Bernsen; Jaap J M Teunissen; Dik J Kwekkeboom; Marion de Jong
Journal:  Clin Transl Imaging       Date:  2014-03-05

2.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

Review 3.  Theranostics of Neuroendocrine Tumors.

Authors:  Sze Ting Lee; Harshad R Kulkarni; Aviral Singh; Richard P Baum
Journal:  Visc Med       Date:  2017-10-20

Review 4.  Radionuclide Therapy for Neuroendocrine Tumors.

Authors:  Mauro Cives; Jonathan Strosberg
Journal:  Curr Oncol Rep       Date:  2017-02       Impact factor: 5.075

Review 5.  [Liver metastases of neuroendocrine tumors].

Authors:  S Nadalin; M Peters; A Königsrainer
Journal:  Chirurgie (Heidelb)       Date:  2022-06-17

Review 6.  Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Authors:  Giuseppe Lo Russo; Sara Pusceddu; Natalie Prinzi; Martina Imbimbo; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Marco Maccauro; Roberto Buzzoni; Ettore Seregni; Filippo de Braud; Marina Chiara Garassino
Journal:  Tumour Biol       Date:  2016-07-27

Review 7.  Targeted radionuclide therapies for pancreatic cancer.

Authors:  M Shah; R Da Silva; C Gravekamp; S K Libutti; T Abraham; E Dadachova
Journal:  Cancer Gene Ther       Date:  2015-07-31       Impact factor: 5.987

8.  Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experience.

Authors:  Tak Geun Oh; Moon Jae Chung; Jeong Yeop Park; Seung Min Bang; Seung Woo Park; Jae Bok Chung; Si Young Song
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

Review 9.  Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives.

Authors:  Nader Hirmas; Raya Jadaan; Akram Al-Ibraheem
Journal:  Nucl Med Mol Imaging       Date:  2018-03-28

10.  Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).

Authors:  Anna Sowa-Staszczak; Dorota Pach; Robert Chrzan; Małgorzata Trofimiuk; Agnieszka Stefańska; Monika Tomaszuk; Maciej Kołodziej; Renata Mikołajczak; Dariusz Pawlak; Alicja Hubalewska-Dydejczyk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.